Skip to main content
. 2005 Dec 15;116(1):90–100. doi: 10.1172/JCI26169

Figure 3.

Figure 3

Effects of SOCS1 silencing on antigen presentation by DCs. (A) Inhibition of preestablished B16 tumor by SOCS1-siRNA DC immunization with TRP2 peptides of different affinities. WT C57BL/6 mice were inoculated s.c. with B16 tumor cells (2.5 × 105) and 3 days later were immunized with 1.5 × 106 TRP2 peptide–pulsed (50 μg/ml; TRP2a or TRP2b), transduced DCs with ex vivo LPS maturation (100 ng/ml). One day after DC transfer, in vivo LPS was administered i.p. (30 μg/mouse) 1 time. Tumor growth curves (n = 6 mice/group) represent 1 of 3 independent experiments. P < 0.01, GFP-siRNA DC compared with SOCS1-siRNA DCs. (B). CD8+ T cell responses induced by SOCS1-siRNA DCs with different TRP2 peptides. CD8+ T cells isolated from the pooled splenocytes of immunized mice (2–3 mice) were subjected to IFN-γ ELISPOT assays stimulated with TRP2a or TRP2b peptide (10 μg/ml). An irrelevant peptide derived from ovalbumin was used as a negative control. *P < 0.01 versus SOCS1-siRNA DC plus TRP2a; **P < 0.01 versus SOCS1-siRNA DC plus TRP2a.